{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:24:32Z","timestamp":1783790672870,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,15]],"date-time":"2015-02-15T00:00:00Z","timestamp":1423958400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12957-015-0455-3","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T11:40:56Z","timestamp":1424173256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer"],"prefix":"10.1186","volume":"13","author":[{"given":"Xingang","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peige","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,15]]},"reference":[{"issue":"7","key":"455_CR1","first-page":"CD007792","volume":"7","author":"A Kucukmetin","year":"2010","unstructured":"Kucukmetin A, Naik R, Galaal K, Bryant A, Dickinson HO. Palliative surgery versus medical management for bowel obstruction in ovarian cancer. Cochrane Database Syst Rev. 2010;7(7):CD007792.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"455_CR2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1634\/theoncologist.2009-0057","volume":"14","author":"DS Chi","year":"2009","unstructured":"Chi DS, Pha\u00ebton R, Miner TJ, Kardos SV, Diaz JP, Leitao Jr MM, et al. A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. Oncologist. 2009;14(8):835\u20139.","journal-title":"Oncologist"},{"issue":"6","key":"455_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jpainsymman.2005.05.018","volume":"30","author":"UA Matulonis","year":"2005","unstructured":"Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, et al. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage. 2005;30(6):563\u20139.","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"455_CR4","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/j.1525-1438.2005.00144.x","volume":"15","author":"G Mangili","year":"2005","unstructured":"Mangili G, Aletti G, Frigerio L, Franchi M, Panacci N, Vigan\u00f2 R, et al. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer. 2005;15(5):830\u20135.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"455_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0090-8258(03)00073-8","volume":"89","author":"B Pothuri","year":"2003","unstructured":"Pothuri B, Vaidya A, Aghajanian C, Venkatraman E, Barakat RR, Chi DS. Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol. 2003;89(2):306\u201313.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"455_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.critrevonc.2011.12.006","volume":"83","author":"S Mercadante","year":"2012","unstructured":"Mercadante S, Porzio G. Octreotide for malignant bowel obstruction: twenty years after. Crit Rev Oncol Hematol. 2012;83(3):388\u201392.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"455_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jjco\/hyn035","volume":"38","author":"Y Shima","year":"2008","unstructured":"Shima Y, Ohtsu A, Shirao K, Sasaki Y. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol. 2008;38(5):354\u20139.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"455_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0885-3924(99)00147-5","volume":"19","author":"C Ripamonti","year":"2000","unstructured":"Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage. 2000;19(1):23\u201334.","journal-title":"J Pain Symptom Manage"},{"key":"455_CR9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/030089169007600417","volume":"76","author":"V Ventafridda","year":"1990","unstructured":"Ventafridda V, Ripamonti C, Caraceni A, Spoldi E, Messina L, De Conno F. The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori. 1990;76:389\u201393.","journal-title":"Tumori."},{"key":"455_CR10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/0885-3924(91)90005-O","volume":"6","author":"F De Conno","year":"1991","unstructured":"De Conno F, Caraceni A, Zecca E, Spoldi E, Ventafridda V. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage. 1991;6:484\u20136.","journal-title":"J Pain Symptom Manage."},{"key":"455_CR11","first-page":"20","volume":"1","author":"J Riley","year":"1994","unstructured":"Riley J, Fallon MT. Octreotide in terminal malignant obstruction of the gastrointestinal tract. Eur J Palliat Care. 1994;1:20\u20132.","journal-title":"Eur J Palliat Care."},{"key":"455_CR12","first-page":"20","volume":"1","author":"MT Fallon","year":"1994","unstructured":"Fallon MT. The physiology of somatostatin and its synthetic analogue, octreotide. Eur J Palliat Care. 1994;1:20\u20132.","journal-title":"Eur J Palliat Care."},{"key":"455_CR13","volume-title":"Cancer pain relief","author":"World Health Organization","year":"1996","unstructured":"World Health Organization. Cancer pain relief. 2nd ed. Geneva: WHO; 1996.","edition":"2"},{"key":"455_CR14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/026921639300700406","volume":"7","author":"S Mercadante","year":"1993","unstructured":"Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med. 1993;7:295\u20139.","journal-title":"Palliat Med."},{"key":"455_CR15","first-page":"323","volume":"2","author":"A Jatoi","year":"2004","unstructured":"Jatoi A, Podratz KC, Gill P, Hartmann LC. Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer. Support Oncol. 2004;2:323\u201334.","journal-title":"Support Oncol."},{"issue":"3","key":"455_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s005200050283","volume":"8","author":"S Mercadante","year":"2000","unstructured":"Mercadante S, Ripamonti C, Casuccio A. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignantinoperable bowel obstruction. Support Care Cancer. 2000;8(3):188\u201391.","journal-title":"Support Care Cancer"},{"issue":"12","key":"455_CR17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3109\/00365529309098305","volume":"28","author":"P Nellg\u00e5rd","year":"1993","unstructured":"Nellg\u00e5rd P, Cassuto J. Inflammation as a major cause of fluid losses in small-bowel obstruction. Scand J Gastroenterol. 1993;28(12):1035\u201341.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"455_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3109\/00365529509093308","volume":"30","author":"P Nellg\u00e5rd","year":"1995","unstructured":"Nellg\u00e5rd P, Boj\u00f6 L, Cassuto J. Importance of vasoactive intestinal peptide and somatostatin for fluid losses in small-bowel obstruction. Scand J Gastroenterol. 1995;30(5):464\u20139.","journal-title":"Scand J Gastroenterol"},{"issue":"14","key":"455_CR19","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1517\/14656566.2011.597382","volume":"12","author":"B O'Connor","year":"2011","unstructured":"O'Connor B, Creedon B. Pharmacological treatment of bowel obstruction in cancer patients. Expert Opin Pharmacother. 2011;12(14):2205\u201314.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"455_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0899-9007(96)91120-X","volume":"12","author":"F Bozzetti","year":"1996","unstructured":"Bozzetti F, Amadori D, Bruera E, Cozzaglio L, Corli O, Filiberti A, et al. Guidelines on artificial nutrition versus hydration in terminal cancer patients. European Association for Palliative Care. Nutrition. 1996;12(3):163\u20137.","journal-title":"Nutrition."},{"issue":"7","key":"455_CR21","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/0885-3924(93)90188-2","volume":"8","author":"FI Burge","year":"1993","unstructured":"Burge FI. Dehydration symptoms of palliative care cancer patients. J Pain Symptom Manage. 1993;8(7):454\u201364.","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"455_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1200\/JCO.2012.44.6518","volume":"31","author":"E Bruera","year":"2013","unstructured":"Bruera E, Hui D, Dalal S, Torres-Vigil I, Torres-Vigil I, Trumble J, et al. Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled randomized trial. J Clin Oncol. 2013;31(1):111\u20138.","journal-title":"J Clin Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-015-0455-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12957-015-0455-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-015-0455-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-015-0455-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T08:27:29Z","timestamp":1630571249000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-015-0455-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,15]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["455"],"URL":"https:\/\/doi.org\/10.1186\/s12957-015-0455-3","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,15]]},"assertion":[{"value":"29 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"50"}}